News | December 17, 2024
SPARC signs LoI with UCSF and Tiller Therapeutics for pre-clinical oncology asset and associated IP
SPARC to receive 55% equity in Tiller Therapeutics
SPARC to receive 55% equity in Tiller Therapeutics
Harnessing advanced data analysis for early detection, prevention and better outcomes
India’s first trial for a novel autologous BCMA directed CAR-T cell therapy in patients with relapsed / refractory multiple myeloma
DKSH has entered into an exclusive partnership with R-Biomeds to bring the necessary medication to patients in Cambodia
The authorization of bortezomib will enhance the company’s ability to deliver advanced cancer solutions in Southeast Asia
More than 10 oral and mini-oral presentations span Pfizer’s extensive Oncology portfolio of approved and investigational therapies
Phase 3 clinical trial designed to evaluate the safety and efficacy of tivozanib in combination with nivolumab
Performed an autologous bone marrow transplant, using the patient’s own cells to reduce the chances of infection and rejection
Merck shared updates on the company’s oncology pipeline and focused R&D approach
With this, for all our USFDA facilities, EIRs are in place
Subscribe To Our Newsletter & Stay Updated
